Breaking Business News: Crown Laboratories to Buy Revance Therapeutics in $924 Million Merger Deal
The Dermatology Digest
AUGUST 12, 2024
“Revance has an impressive track record in developing innovative aesthetics offerings that will complement Crown’s innovative line of skincare products. . “Revance has an impressive track record in developing innovative aesthetics offerings that will complement Crown’s innovative line of skincare products.
Let's personalize your content